Compare SDRL & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDRL | WGS |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | 3000 | N/A |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2018 | 2020 |
| Metric | SDRL | WGS |
|---|---|---|
| Price | $49.14 | $67.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $54.00 | ★ $93.50 |
| AVG Volume (30 Days) | 522.6K | ★ 662.9K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.61 | ★ 62.37 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,437,000,000.00 | $427,539,000.00 |
| Revenue This Year | $13.68 | $12.70 |
| Revenue Next Year | $8.22 | $24.31 |
| P/E Ratio | $136.53 | ★ N/A |
| Revenue Growth | 3.75 | ★ 39.97 |
| 52 Week Low | $28.10 | $32.21 |
| 52 Week High | $55.47 | $170.87 |
| Indicator | SDRL | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 40.47 |
| Support Level | $45.22 | $56.36 |
| Resistance Level | $49.93 | $73.04 |
| Average True Range (ATR) | 2.11 | 4.84 |
| MACD | 0.36 | 0.10 |
| Stochastic Oscillator | 80.90 | 26.15 |
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, and others. The company derives maximum revenue from Brazil.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.